![Neda AMINI | Doctor of Medicine | Johns Hopkins Medicine, Maryland | JHUSOM | Department of Surgery | Research profile Neda AMINI | Doctor of Medicine | Johns Hopkins Medicine, Maryland | JHUSOM | Department of Surgery | Research profile](https://i1.rgstatic.net/ii/profile.image/360525570560000-1462967402358_Q512/Neda-Amini-3.jpg)
Neda AMINI | Doctor of Medicine | Johns Hopkins Medicine, Maryland | JHUSOM | Department of Surgery | Research profile
Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases
![Maryann TRANQUILLI | Clinical nurse aortic research | Yale University, CT | YU | Department of Cardiothoracic Surgery | Research profile Maryann TRANQUILLI | Clinical nurse aortic research | Yale University, CT | YU | Department of Cardiothoracic Surgery | Research profile](https://www.researchgate.net/publication/355895318/figure/fig1/AS:11431281127270735@1678993790210/Post-Transplant-Aneurysm-Images_Q320.jpg)
Maryann TRANQUILLI | Clinical nurse aortic research | Yale University, CT | YU | Department of Cardiothoracic Surgery | Research profile
1 Part A. PERSONAL INFORMATION Name and Surname Michael Vassilakopoulos Researcher numbers Researcher ID K-2324-2017 Orcid code
![Peter MUSCARELLA | Chief of Surgery | Niagara Falls Memorial Medical Center, Niagara Falls | Surgery | Research profile Peter MUSCARELLA | Chief of Surgery | Niagara Falls Memorial Medical Center, Niagara Falls | Surgery | Research profile](https://i1.rgstatic.net/ii/profile.image/300442438389760-1448642467250_Q128/Peter-Muscarella.jpg)
Peter MUSCARELLA | Chief of Surgery | Niagara Falls Memorial Medical Center, Niagara Falls | Surgery | Research profile
![PDF) The impact of portal vein resection on outcomes for hilar cholangiocarcinoma | Richard Schulick - Academia.edu PDF) The impact of portal vein resection on outcomes for hilar cholangiocarcinoma | Richard Schulick - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/40018400/mini_magick20190222-11455-nqfwyc.png?1550827409)
PDF) The impact of portal vein resection on outcomes for hilar cholangiocarcinoma | Richard Schulick - Academia.edu
![Lauren POSTLEWAIT | Professor (Assistant) | Emory University, GA | EU | Department of Surgery | Research profile Lauren POSTLEWAIT | Professor (Assistant) | Emory University, GA | EU | Department of Surgery | Research profile](https://i1.rgstatic.net/ii/profile.image/993739812110336-1613937442991_Q512/Lauren-Postlewait.jpg)
Lauren POSTLEWAIT | Professor (Assistant) | Emory University, GA | EU | Department of Surgery | Research profile
![Timothy PAWLIK | Chair, Department of Surgery, Professor of Surgery and Oncology, The Urban Meyer III and Shelley Meyer Chair for Cancer Research | MD, MPH, PhD | The Ohio State University, Timothy PAWLIK | Chair, Department of Surgery, Professor of Surgery and Oncology, The Urban Meyer III and Shelley Meyer Chair for Cancer Research | MD, MPH, PhD | The Ohio State University,](https://i1.rgstatic.net/ii/profile.image/272831678251017-1442059549776_Q512/Timothy-Pawlik.jpg)
Timothy PAWLIK | Chair, Department of Surgery, Professor of Surgery and Oncology, The Urban Meyer III and Shelley Meyer Chair for Cancer Research | MD, MPH, PhD | The Ohio State University,
![PDF) Antigen-Directed Cancer Surgery for Primary Colorectal Cancer: 15-Year Survival Analysis: A Reply PDF) Antigen-Directed Cancer Surgery for Primary Colorectal Cancer: 15-Year Survival Analysis: A Reply](https://i1.rgstatic.net/ii/profile.image/681435081998337-1539478192257_Q64/Ioannis-Hatzaras-2.jpg)
PDF) Antigen-Directed Cancer Surgery for Primary Colorectal Cancer: 15-Year Survival Analysis: A Reply
Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepati
![PDF) An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalised Immunotherapy and FGFR2 Inhibiter PDF) An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalised Immunotherapy and FGFR2 Inhibiter](https://i1.rgstatic.net/publication/376217785_An_Advanced_Intrahepatic_Cholangiocarcinoma_Patient_Benefits_from_Personalised_Immunotherapy_and_FGFR2_Inhibiter/links/656f1bb95985071c7bf06594/largepreview.png)